| Medicine in it | Semaglutide | Semaglutide |
| Made by | Novo Nordisk | Novo Nordisk |
| Receptors it acts on | One: the GLP-1 receptor | One: the GLP-1 receptor |
| Approved for | Type 2 diabetes in adults: blood sugar control, and lowering the risk of heart attack, stroke or cardiovascular death in those with heart disease, and of kidney disease getting worse in those with chronic kidney disease | Weight: losing excess weight and keeping it off, for adults and children 12 and older with obesity, and adults with overweight and a weight-related condition. Also lowering the risk of heart attack, stroke or cardiovascular death in adults with heart disease, and (the injection) a liver disease, MASH, with moderate to advanced scarring |
| How it's taken | An injection once a week | An injection once a week, or a tablet once a day |
| Starting dose | 0.25 mg a week for 4 weeks, then 0.5 mg | Injection: 0.25 mg a week for 4 weeks. Tablet: 1.5 mg a day for 30 days |
| Dose it builds up to | 0.5 mg, 1 mg or 2 mg a week, raised if more blood sugar control is needed | Usually 2.4 mg a week (injection), or 25 mg a day (tablets) |
| Half-life | About 1 week | About 1 week |
| If you miss a dose | Take it within 5 days; after that, skip it | Injection: goes by your next dose. More than 2 days away, take it; less, skip it |